Role of α1-blockers in the current management of hypertension
There is emerging evidence that α1-blockers can be safely used in the treatment of hypertension. These drugs can be used in almost all hypertensive patients for blood pressure control. However, there are several special indications. Benign prostatic hyperplasia is a compelling indication of α1-block...
Saved in:
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Published: |
Wiley
2022
|
Subjects: | |
Online Access: | http://eprints.sunway.edu.my/3087/ https://doi.org/10.1111/jch.14556 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
my.sunway.eprints.3087 |
---|---|
record_format |
eprints |
spelling |
my.sunway.eprints.30872024-08-12T23:47:39Z http://eprints.sunway.edu.my/3087/ Role of α1-blockers in the current management of hypertension Li, Hua Xu, Ting Yan Chia, Yook Chin * Buranakitjaroen, Peera Cheng, Hao Min Huynh, Minh Van Sogunuru, Guru Prasad Tay, Jam Chin Wang, Tzung-Dau Kario, Kazuomi Wang, Ji-Guang RC Internal medicine There is emerging evidence that α1-blockers can be safely used in the treatment of hypertension. These drugs can be used in almost all hypertensive patients for blood pressure control. However, there are several special indications. Benign prostatic hyperplasia is a compelling indication of α1-blockers, because of the dual treatment effect on both high blood pressure and lower urinary tract symptoms. Many patients with resistant hypertension would require α1-blockers as add-on therapy. Primary aldosteronism screen is a rapidly increasing clinical demand in the management of hypertension, where α1-blockers are useful for blood pressure control in the preparation for the measurement of plasma aldosterone and renin. Nonetheless, α1-blockers have to be used under several considerations. Among the currently available agents, only long-acting α1-blockers, such as doxazosin gastrointestinal therapeutic system 4-8 mg daily and terazosin 2-4 mg daily, should be chosen. Orthostatic hypotension is a concern with the use of α1-blockers especially in the elderly, and requires careful initial bedtime dosing and avoiding overdosing. Fluid retention is potentially also a concern, which may be overcome by combining an α1-blocker with a diuretic. Wiley 2022 Article PeerReviewed Li, Hua and Xu, Ting Yan and Chia, Yook Chin * and Buranakitjaroen, Peera and Cheng, Hao Min and Huynh, Minh Van and Sogunuru, Guru Prasad and Tay, Jam Chin and Wang, Tzung-Dau and Kario, Kazuomi and Wang, Ji-Guang (2022) Role of α1-blockers in the current management of hypertension. The Journal of Clinical Hypertension, 24 (9). ISSN 0748-450X https://doi.org/10.1111/jch.14556 10.1111/jch.14556 |
institution |
Sunway University |
building |
Sunway Campus Library |
collection |
Institutional Repository |
continent |
Asia |
country |
Malaysia |
content_provider |
Sunway University |
content_source |
Sunway Institutional Repository |
url_provider |
http://eprints.sunway.edu.my/ |
topic |
RC Internal medicine |
spellingShingle |
RC Internal medicine Li, Hua Xu, Ting Yan Chia, Yook Chin * Buranakitjaroen, Peera Cheng, Hao Min Huynh, Minh Van Sogunuru, Guru Prasad Tay, Jam Chin Wang, Tzung-Dau Kario, Kazuomi Wang, Ji-Guang Role of α1-blockers in the current management of hypertension |
description |
There is emerging evidence that α1-blockers can be safely used in the treatment of hypertension. These drugs can be used in almost all hypertensive patients for blood pressure control. However, there are several special indications. Benign prostatic hyperplasia is a compelling indication of α1-blockers, because of the dual treatment effect on both high blood pressure and lower urinary tract symptoms. Many patients with resistant hypertension would require α1-blockers as add-on therapy. Primary aldosteronism screen is a rapidly increasing clinical demand in the management of hypertension, where α1-blockers are useful for blood pressure control in the preparation for the measurement of plasma aldosterone and renin. Nonetheless, α1-blockers have to be used under several considerations. Among the currently available agents, only long-acting α1-blockers, such as doxazosin gastrointestinal therapeutic system 4-8 mg daily and terazosin 2-4 mg daily, should be chosen. Orthostatic hypotension is a concern with the use of α1-blockers especially in the elderly, and requires careful initial bedtime dosing and avoiding overdosing. Fluid retention is potentially also a concern, which may be overcome by combining an α1-blocker with a diuretic. |
format |
Article |
author |
Li, Hua Xu, Ting Yan Chia, Yook Chin * Buranakitjaroen, Peera Cheng, Hao Min Huynh, Minh Van Sogunuru, Guru Prasad Tay, Jam Chin Wang, Tzung-Dau Kario, Kazuomi Wang, Ji-Guang |
author_facet |
Li, Hua Xu, Ting Yan Chia, Yook Chin * Buranakitjaroen, Peera Cheng, Hao Min Huynh, Minh Van Sogunuru, Guru Prasad Tay, Jam Chin Wang, Tzung-Dau Kario, Kazuomi Wang, Ji-Guang |
author_sort |
Li, Hua |
title |
Role of α1-blockers in the current management of hypertension |
title_short |
Role of α1-blockers in the current management of hypertension |
title_full |
Role of α1-blockers in the current management of hypertension |
title_fullStr |
Role of α1-blockers in the current management of hypertension |
title_full_unstemmed |
Role of α1-blockers in the current management of hypertension |
title_sort |
role of α1-blockers in the current management of hypertension |
publisher |
Wiley |
publishDate |
2022 |
url |
http://eprints.sunway.edu.my/3087/ https://doi.org/10.1111/jch.14556 |
_version_ |
1808975639884070912 |
score |
13.19449 |